No Data
No Data
No Data
No Data
No Data
An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued
Key Insights Sirio Pharma's estimated fair value is CN¥51.11 based on 2 Stage Free Cash Flow to Equity Sirio Pharma is estimated to be 24% undervalued based on current share price of CN¥39.07 Ana
Simply Wall StApr 23 23:43 ET
Xianle Health (300791.SZ) released 2023 annual results, with net profit of 281 million yuan, an increase of 32.39% over the previous year
Xianle Health (300791.SZ) released its 2023 annual report. The company achieved operating income of 35 during the reporting period...
Zhitong FinanceApr 21 05:49 ET
Softgel Capsules Market Size, Share & Trends Analysis Report 2023-2030, Featuring Fuji Capsule, Sirio Pharma, CAPTEK Softgel, Catalent, EuroCaps, Aenova, ProCaps Laboratories and Soft Gel Technologies
Yahoo FinanceMar 28 11:52 ET
Xianle Health (300791.SZ): The repurchase was completed with a cumulative cost of 398.997 million yuan to repurchase 1.285,600 shares
Gelonghui, March 19, 丨 Xianle Health (300791.SZ) announced that as of March 18, 2024, the company had repurchased 1.285,600 shares of the company's shares through a dedicated securities account, accounting for 0.71% of the company's current total share capital of 181,562,337 shares. The highest transaction price was 35.88 yuan/share, the minimum transaction price was 25.29 yuan/share, and the total transaction amount was RMB 398.997 million (excluding transaction fees). At this point, the implementation of the company's share repurchase plan has been completed.
Gelonghui FinanceMar 19 07:05 ET
Zheng Liqun, Deputy General Manager and Secretary of the Board of Directors of Xianle Health (300791.SZ), increased her holdings by 27,700 shares
Xianle Health (300791.SZ) announced that Zheng Liqun, the company's deputy general manager and secretary of the board of directors, will implement the plan to increase her holdings...
Zhitong FinanceMar 10 03:46 ET
Sirio Pharma Co., Ltd. (SZSE:300791) Surges 7.0%; Private Companies Who Own 43% Shares Profited Along With Insiders
Key Insights The considerable ownership by private companies in Sirio Pharma indicates that they collectively have a greater say in management and business strategy 53% of the business is held by th
Simply Wall StMar 6 20:16 ET
No Data
No Data